Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Bromocriptine Reduces Growth Hormone in Acromegaly

Bromocriptine Reduces Growth Hormone in Acromegaly Abstract • We assessed serum growth hormone (GH) levels in ten patients with acromegaly during a 24-hour profile and a 75-g oral glucose tolerance test (GTT). Serum GH levels were measured after five weeks of bromocriptine mesylate therapy, 20 mg daily (P1), after five weeks without bromocriptine mesylate therapy (P2), and again five weeks following restarting treatment with bromocriptine, 20 mg daily (P3). During the 24-hour profile, the following occurred: (1) mean serum GH level of the group was lower during P1 (20.5 mU/L) and P3 (20.8 mU/L) than P2 (49.6 mU/L); (2) in six individual patients during P1 and P3, there was a significant reduction in the mean serum GH value; and (3) a marked circadian variation in the serum GH value was present both with and without the drug therapy in five patients. During the GTT, the mean serum GH value was lower during P1 (18.4 mU/L) and P3 References 1. Liuzzi A, Chiodini PG, Botalla L, et al: Decreased plasma growth hormone (GH) levels in acromegalics following CB 154 (2-Br-ergocryptine) administration. J Clin Endocrinol Metabol 1974;38:910-912.Crossref 2. Thorner MO, Chait A, Aitken M, et al: Bromocriptine treatment of acromegaly. Br Med J 1975;1:299-303.Crossref 3. Sachdev Y, Gomez-Pan A, Tunbridge WMG, et al: Bromocriptine therapy in acromegaly. Lancet 1975;2:1164-1168.Crossref 4. Belforte L, Camanni F, Chiodini PG, et al: Long-term treatment with 2-Br-alpha-ergocryptine in acromegaly. Acta Endocrinol 1977;85:235-248. 5. Wass JAH, Thorner MO, Morris DV, et al: Long-term treatment of acromegaly with bromocriptine. Br Med J 1977;1:875-878.Crossref 6. Cassar J, Mashiter K, Joplin GF: Bromocriptine treatment of acromegaly. Metabolism 1977;26:539-546.Crossref 7. Clayton RN, Vrionides Y, Lynch SS, et al: Response of acromegaly to long-term bromocriptine therapy: A biochemical and clinical assessment. Acta Endocrinol 1978;89:469-482. 8. Eskildsen PC, Svendsen PA, Vang L, et al: Long-term treatment of acromegaly with bromocriptine. Acta Endocrinol 1978;87:687-700. 9. Feek CM, Bevan JS, Taylor S, et al: The effect of bromocriptine on insulin secretion and glucose intolerance in patients with acromegaly. Clin Endocrinol 1981;15:473-478.Crossref 10. Pelkonen R, Ylikahri R, Karonen SL: Bromocriptine treatment of patients with acromegaly resistant to conventional therapy. Clin Endocrinol 1980;12:219-224.Crossref 11. Wass JAH, Cudworth AG, Botazzo GF, et al: An assessment of glucose intolerance in acromegaly and its response to medical treatment. Clin Endocrinol 1980;12:53-59.Crossref 12. Thorner MO, Besser GM, Wass JAH, et al: Bromocriptine in acromegaly. N Engl J Med 1981;305:1092.Crossref 13. Lindholm J, Riishede J, Vestergaard S, et al: No effect of bromocriptine in acromegaly. N Engl J Med 1981;304:1450-1454.Crossref 14. Summers VK, Hipkin LJ, Diver MJ, et al: Treatment of acromegaly with bromocriptine. J Clin Endocrinol Metabol 1977;40:904-906.Crossref 15. Dunn PJ, Donald RA, Espiner EA: Bromocriptine suppression of plasma growth hormone in acromegaly. Clin Endocrinol 1977;7:273-281.Crossref 16. Boden G, Soeldner JS: A sensitive double antibody radioimmunoassay for human growth hormone (hgh): Levels of serum hgh following rapid tolbutamide infusion. Diabetologia 1967;3:413-421.Crossref 17. Edwards R: The development and use of PEG-assisted second antibody precipitation as a separation technique in radioimmunoassay , in Hunter WM, Corrik JKT (eds): Immunoassays for Clinical Chemistry , ed 2. Edinburgh, Churchill Livingstone Inc, 1983, pp 139-146. 18. Lindholm J, Riishede J, Vestergaard S, et al: Bromocriptine in acromegaly. N Engl J Med 1981;305:1092-1093.Crossref 19. Nortier JWR, Croughs RJM, Thijssen JHH, et al: Plasma growth hormone suppressive effect of bromocriptine in acromegaly: Evaluation of plasma GH day profiles and plasma GH concentrations during oral glucose tolerance tests. Clin Endocrinol 1984;20:565-571.Crossref 20. Lamberts SWJ, Liuzzi A, Chiodini PG, et al: The value of plasma prolactin in the prediction of responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly. Eur J Clin Invest 1982;12:151-155.Crossref 21. Cryer PE, Daughaday WH: Regulation of growth hormone secretion in acromegaly. J Clin Endocrinol Metabol 1969;29:386-393.Crossref 22. Carlson HE, Gillin JC, Gorden P, et al: Absence of sleep-related growth hormone peaks in normal subjects and in acromegaly. J Clin Endocrinol Metabol 1972;34:1102-1105.Crossref 23. Chihara K, Kato Y, Abe H, et al: Sleep-related growth hormone release following 2-bromo-alpha-ergocriptine treatment in acromegalic patients. J Clin Endocrinol Metabol 1977;44:78-84.Crossref 24. Clemmons DR, Van Wyk JJ, Ridgeway EC, et al: Evaluation of acromegaly by radioimmunoassay of somatomedin C. N Engl J Med 1979;301:1138-1142.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Internal Medicine American Medical Association

Loading next page...
 
/lp/american-medical-association/bromocriptine-reduces-growth-hormone-in-acromegaly-tyd5zrqdTZ

References (25)

Publisher
American Medical Association
Copyright
Copyright © 1986 American Medical Association. All Rights Reserved.
ISSN
0003-9926
eISSN
1538-3679
DOI
10.1001/archinte.1986.00360180149023
Publisher site
See Article on Publisher Site

Abstract

Abstract • We assessed serum growth hormone (GH) levels in ten patients with acromegaly during a 24-hour profile and a 75-g oral glucose tolerance test (GTT). Serum GH levels were measured after five weeks of bromocriptine mesylate therapy, 20 mg daily (P1), after five weeks without bromocriptine mesylate therapy (P2), and again five weeks following restarting treatment with bromocriptine, 20 mg daily (P3). During the 24-hour profile, the following occurred: (1) mean serum GH level of the group was lower during P1 (20.5 mU/L) and P3 (20.8 mU/L) than P2 (49.6 mU/L); (2) in six individual patients during P1 and P3, there was a significant reduction in the mean serum GH value; and (3) a marked circadian variation in the serum GH value was present both with and without the drug therapy in five patients. During the GTT, the mean serum GH value was lower during P1 (18.4 mU/L) and P3 References 1. Liuzzi A, Chiodini PG, Botalla L, et al: Decreased plasma growth hormone (GH) levels in acromegalics following CB 154 (2-Br-ergocryptine) administration. J Clin Endocrinol Metabol 1974;38:910-912.Crossref 2. Thorner MO, Chait A, Aitken M, et al: Bromocriptine treatment of acromegaly. Br Med J 1975;1:299-303.Crossref 3. Sachdev Y, Gomez-Pan A, Tunbridge WMG, et al: Bromocriptine therapy in acromegaly. Lancet 1975;2:1164-1168.Crossref 4. Belforte L, Camanni F, Chiodini PG, et al: Long-term treatment with 2-Br-alpha-ergocryptine in acromegaly. Acta Endocrinol 1977;85:235-248. 5. Wass JAH, Thorner MO, Morris DV, et al: Long-term treatment of acromegaly with bromocriptine. Br Med J 1977;1:875-878.Crossref 6. Cassar J, Mashiter K, Joplin GF: Bromocriptine treatment of acromegaly. Metabolism 1977;26:539-546.Crossref 7. Clayton RN, Vrionides Y, Lynch SS, et al: Response of acromegaly to long-term bromocriptine therapy: A biochemical and clinical assessment. Acta Endocrinol 1978;89:469-482. 8. Eskildsen PC, Svendsen PA, Vang L, et al: Long-term treatment of acromegaly with bromocriptine. Acta Endocrinol 1978;87:687-700. 9. Feek CM, Bevan JS, Taylor S, et al: The effect of bromocriptine on insulin secretion and glucose intolerance in patients with acromegaly. Clin Endocrinol 1981;15:473-478.Crossref 10. Pelkonen R, Ylikahri R, Karonen SL: Bromocriptine treatment of patients with acromegaly resistant to conventional therapy. Clin Endocrinol 1980;12:219-224.Crossref 11. Wass JAH, Cudworth AG, Botazzo GF, et al: An assessment of glucose intolerance in acromegaly and its response to medical treatment. Clin Endocrinol 1980;12:53-59.Crossref 12. Thorner MO, Besser GM, Wass JAH, et al: Bromocriptine in acromegaly. N Engl J Med 1981;305:1092.Crossref 13. Lindholm J, Riishede J, Vestergaard S, et al: No effect of bromocriptine in acromegaly. N Engl J Med 1981;304:1450-1454.Crossref 14. Summers VK, Hipkin LJ, Diver MJ, et al: Treatment of acromegaly with bromocriptine. J Clin Endocrinol Metabol 1977;40:904-906.Crossref 15. Dunn PJ, Donald RA, Espiner EA: Bromocriptine suppression of plasma growth hormone in acromegaly. Clin Endocrinol 1977;7:273-281.Crossref 16. Boden G, Soeldner JS: A sensitive double antibody radioimmunoassay for human growth hormone (hgh): Levels of serum hgh following rapid tolbutamide infusion. Diabetologia 1967;3:413-421.Crossref 17. Edwards R: The development and use of PEG-assisted second antibody precipitation as a separation technique in radioimmunoassay , in Hunter WM, Corrik JKT (eds): Immunoassays for Clinical Chemistry , ed 2. Edinburgh, Churchill Livingstone Inc, 1983, pp 139-146. 18. Lindholm J, Riishede J, Vestergaard S, et al: Bromocriptine in acromegaly. N Engl J Med 1981;305:1092-1093.Crossref 19. Nortier JWR, Croughs RJM, Thijssen JHH, et al: Plasma growth hormone suppressive effect of bromocriptine in acromegaly: Evaluation of plasma GH day profiles and plasma GH concentrations during oral glucose tolerance tests. Clin Endocrinol 1984;20:565-571.Crossref 20. Lamberts SWJ, Liuzzi A, Chiodini PG, et al: The value of plasma prolactin in the prediction of responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly. Eur J Clin Invest 1982;12:151-155.Crossref 21. Cryer PE, Daughaday WH: Regulation of growth hormone secretion in acromegaly. J Clin Endocrinol Metabol 1969;29:386-393.Crossref 22. Carlson HE, Gillin JC, Gorden P, et al: Absence of sleep-related growth hormone peaks in normal subjects and in acromegaly. J Clin Endocrinol Metabol 1972;34:1102-1105.Crossref 23. Chihara K, Kato Y, Abe H, et al: Sleep-related growth hormone release following 2-bromo-alpha-ergocriptine treatment in acromegalic patients. J Clin Endocrinol Metabol 1977;44:78-84.Crossref 24. Clemmons DR, Van Wyk JJ, Ridgeway EC, et al: Evaluation of acromegaly by radioimmunoassay of somatomedin C. N Engl J Med 1979;301:1138-1142.Crossref

Journal

Archives of Internal MedicineAmerican Medical Association

Published: Jun 1, 1986

There are no references for this article.